SU-DIPG-13 NTCC?弥漫型内因性脑桥神经胶细胞瘤细胞株cell line-BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

价　　格：￥99850
货　　号：NTCC?_IT41 SU-DIPG-13
产　　地：北京

竭诚为您服务！

BioVector NTCC典型培养物保藏中心: 联系人：Dr.Xu, Biovector NTCC Inc.; 电话：400-800-2947 工作QQ:1843439339 (微信同号); 邮件：Biovector@163.com; 手机：18901268599; 地址：北京; 已注册

详细信息
咨询记录(共0条)

The SU-DIPG-13 cell line is a patient-derived cell line used in studies of diffuse intrinsic pontine glioma (DIPG), a fatal pediatric brain tumor:

Stem-like properties
ALDH+ SU-DIPG XIII cells have greater proliferation and neurosphere size than ALDH- cells, suggesting the presence of cancer stem cells in DIPG tumors.
Synergistic activity
The combination of ONC201 and HDAC inhibitors, such as panobinostat or romidepsin, has synergistic activity against SU-DIPG-13 cells.
Transcriptional vulnerabilities
DIPG cells are vulnerable to transcriptional disruption through bromodomain inhibition or CDK7 blockade.
CDK7 inhibition
THZ1, a CDK7 inhibitor, can reduce the growth of DIPG xenografts in vivo and increase median survival in mice.

DIPG is the leading cause of brain tumor-related death in children. The standard treatment is radiation alone, as complete resection is not possible and conventional chemotherapy is ineffective.

Cell pictures: